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Substantial evidence exists supporting a major contributory role 
for genes in the causation of schizophrenia,1-3 a psychiatric illness 
characterised by hallucinations, delusions, disorganised thinking, 
alogia, avolition and other negative symptoms.4
A micro-deletion at chromosome 22q11, the most frequent 
interstitial deletion found in humans, has been implicated in the 
onset of schizophrenia. This aberration occurs in approximately 
1 in every 4 000 live births (a familial type occurs in <5% of 
reported cases) and its occurrence is associated with a variable 
phenotype. The prevalence of psychosis in those with 22q11 
deletion syndrome is high (~25%), suggesting that haplo-
insufficiency of a gene or genes in this region may confer a 
substantially increased risk.5 It is therefore not surprising that 
approximately 1 in 4 children with 22q11 deletion syndrome 
could develop schizophrenia over their lifetime.6 
 The 22q11 micro-deletions have been characterised and mainly 
involve two areas of 3 Mb (87% of cases) and 1.5 Mb (8% of 
cases), respectively. The critical overlapping area between these 
two areas and smaller deletions described in selected cases has led 
to the identification of the ‘schizophrenia critical region’ (1.5 Mb 
in size). This area probably contributes via hemizygous deletion 
(30 genes located in area) to the development of schizophrenia in 
approximately 2% of cases. However it is still uncertain how large the 
contribution of non-deletion variants in this region may be, especially 
if we consider that the PRODH, ZDHHC8 and COMT genes are 
located in or around this area.6  
With regard to the 22q11 micro-deletion, it appears that 
prevalence differs in different cultural and ethnic groups. For 
example, Karayiourgou and Gogos6 state that ‘... the lowest rate 
(0.3%) has been reported in a case sample from Japan’. Wiehahn 
et al.7 found that among Afrikaner schizophrenia patients from South 
Africa, there is a prevalence of 2.4% of chromosome 22q11 micro-
deletions. Phylogenetically, the Afrikaners are closer to European 
ethnic groups. 
However, to date, no cytogenetic studies have focused exclusively 
on the prevalence of chromosome 22q11 micro-deletions in the black 
African population. There is a paucity of data on schizophrenia and 
other mental illnesses in this group.8  
Aims and objectives
Our study focused on a Nguni-speaking population group (the 
Xhosa) who live mainly in the Eastern and Western Cape provinces 
of South Africa. We aimed to screen for 22q11 micro-deletions in this 
group to contribute to the genetic profile of an African sample with 
schizophrenia. 
Methods
The Xhosa people are the second largest and southernmost 
indigenous African population within South Africa and belong to 
the Nguni linguistic group. Given the historical and geographical 
factors that influenced their identity, the Xhosa population can 
be regarded as representing a culturally homogenous grouping.9 
Forming part of a larger ‘Genetics of Schizophrenia’ study, 295 
Xhosa schizophrenia patients and 240 healthy Xhosa controls 
participated in this study. Micro-deletions of the 22q11 locus 
were analysed using fluorescent in situ hybridisation (FISH) and/
or molecular analyses. Participants provided written, informed 
consent as approved by the Committee for Human Research of 
Stellenbosch University, South Africa. All were of Xhosa ethnic 
origin (4/4 grandparents reported to be of Xhosa origin), while 
schizophrenia patients additionally met the following criteria: (i) 
inclusion criteria: (a) structured clinical interview (diagnostic 
interview for genetic studies, including schedules for the assessment 
of negative and positive symptoms); (b) diagnosis of schizophrenia 
or schizo-affective disorder (DSM-IV criteria); and (ii) exclusion 
criteria: subjects with known medical disorders that may cause 
psychosis were excluded.
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FISH analyses 
Twenty millilitres of peripheral venous blood was collected from 
each participant. FISH analyses were performed on a sub-group of 
the Xhosa schizophrenia patients (i.e. 110 patients, Table I) according 
to the standardised procedure of the local accredited diagnostic 
laboratory (UNISTEL), employing the use of the LSI TUPLE 1 
spectrum orange probe.
Molecular analyses (TaqmanTM copy number assay)
As an additional verification for the presence or absence of 22q11 
micro-deletions, data were used from a Xhosa schizophrenia 
candidate 22q11 gene study (G Wright, 2011 – unpublished data). 
Genotypes for 14 single nucleotide polymorphisms (SNPs) in the 
catechol-O-methyltransferase (COMT) gene were available for 238 
Xhosa schizophrenia patients (including the 53 of the FISH samples) 
and 240 healthy Xhosa control individuals (Table I) and were used 
to identify homozygous samples for all the polymorphisms (Wright, 
unpublished data). The rationale for this selection criterion is that 
hemizygous samples, carrying a micro-deletion of this region, would 
present as homozygotes if conventional genotyping assays are used. 
Briefly, a TaqmanTM copy number assay (Applied Biosystems, 
Foster City, CA, USA) was used to perform a duplex real-time 
polymerase chain reaction (PCR) including probes for the 22q11 
COMT region (Hs01482169_cn) as well as a reference gene (RNAse 
P). Quadruplicate PCRs were performed for each sample and 
genomic DNA from a known 22qDS patient was included in every 
run, serving as a positive control. Reaction conditions, plate setup, 
PCR cycling and subsequent analysis of the data were performed as 
described in Drögemöller et al.10
Results 
No chromosome 22q11 micro-deletions were detected in the sub-
group of samples that underwent FISH analyses. Because of the 
absence of micro-deletions in these patients, we screened Xhosa 
samples that had also been analysed for a schizophrenia candidate 
22q11 gene study (Table I). Genotype data from this study identified 
a total of 12 Xhosa samples (from 8 schizophrenia patients and 4 
controls) that met the inclusion criterion for duplex real-time PCR 
analysis and were successfully screened for 22q11 micro-deletions. 
The 22qDS patient positive control was correctly identified as 
carrying a single copy of the 22q11 locus in all runs. All the Xhosa 
samples, however, were predicted to have 2 copies of the 22q11 locus 
(calculated copy number 1.58 - 2.19; confidence ≥95%) and were 
therefore negative for micro-deletions in this region.  
These data confirm the absence of 22q11 micro-deletions in the 
Xhosa cohort through molecular and cytogenetic analyses. 
Discussion
To our knowledge, this is the first study exploring the prevalence of 
chromosome 22q11 micro-deletions in an ethnically homogenous 
indigenous African sample and its relationship to schizophrenia. We 
found no deletions of this chromosome in our sample, representing 
535 Xhosa individuals (i.e. 295 Xhosa schizophrenia patients and 240 
healthy Xhosa controls). We acknowledge that type II errors may 
have occurred, but at the least this finding suggests an extremely low 
prevalence of chromosome 22q11 micro-deletions in this population 
group.  Our findings are in contrast to those of Mulle et al.,1 who 
identified 29 (0.47%) deletions of the 22q11 region among 6 107 
schizophrenia patients of Ashkenazi Jewish descent living in the USA. 
The lack of any chromosome 22q11 micro-deletion-positive 
cases means that we cannot comment on any phenotype-genotype 
relationships. However, given the previously reported low obsessive-
compulsive disorder (OCD) prevalence in Xhosa schizophrenic 
subjects,8 this is an intriguing finding. Larger extended studies are 
needed to detect a low rate of chromosome 22q11 micro-deletions.  
This pilot study further raises the possibility that the Xhosa 
schizophrenia population may have unique susceptibility or protective 
factors that influence comorbidity patterns in schizophrenia. 
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Table I. Number of Xhosa samples used for the different analyses performed
Total* FISH analyses Molecular analyses Overlap†
Xhosa schizophrenia 295 110 238 53
Xhosa control 240 0 240 0
*Total number of unique Xhosa samples. 
†Samples that were analysed using FISH and also had genotype data available.
